| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -8,965 |
| Depreciation and amortization | 13 |
| Amortization of right-of-use assets | 105 |
| Share-based compensation expense | 5,180 |
| Trade and other receivables | -30 |
| Prepaid and other assets | -156 |
| Trade and other payables | 125 |
| Accrued employee benefits | 37 |
| Lease liabilities | -32 |
| Net cash used in operating activities | -3,351 |
| Net cash used in investing activities | 0 |
| Proceeds from exercise of pre-funded warrants, series 2 warrants and common warrants | 0 |
| Net cash provided by financing activities | 0 |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | 86 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -3,265 |
| Cash and cash equivalents at beginning of period | 97,857 |
| Cash and cash equivalents at end of period | 94,592 |
Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. (BNTC)